secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-121810
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango reports Q3 loss $29.2M; TNG462 shows durable activity; PRMT5 program advanced
--------------------------------------------------------------------------------

- TNG462 demonstrated clinical activity across multiple tumor types; 43% ORR in cholangiocarcinoma (n=7); median time on treatment 24 weeks and increasing.
- Multiple TNG462 combos planned 1H 2025 with RAS(ON) inhibitors (Revolution Medicines), osimertinib, and pembrolizumab.
- TNG908 enrollment stopped due to insufficient CNS exposure in glioblastoma; next-gen brain-penetrant TNG456 enters phase 1/2 1H 2025.
- Cash $293M as of Sept 30, 2024; cash runway into 3Q 2026; Q3 net loss $29.2M ($0.27/shr) vs $22.3M ($0.23/shr) year ago.
- Maeve Waldron-Lynch, M.D. joins as SVP Head of Clinical Development, bringing late-stage oncology regulatory experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017024121810/0000950170-24-121810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017024121810/tngx-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-121810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer